| Roche to announce CLL8 trial results for CLL treatment | Posted on 07/12/2009 in Scientific Roche will unveil the results of a medical trial into its chronic lymphocytic leukaemia (CLL) treatment CLL8 at a forthcoming conference.
The phase III trial was a randomised study examining whether patients with previously untreated CLL live longer when they receive MabThera/Rituxan plus fludarabine and cyclophosphamide (FC) chemotherapy, rather than FC alone.
Details of the role MabThera/Rituxan plays in the treatment of CLL will be disclosed, as well as its suitability as a therapy for large B-cell lymphoma and indolent non-Hodgkin's lymphoma.
According to the firm, the data confirms MabThera/Rituxan as the standard of care in haematological cancers, "with over 1.9 million patient exposures recorded worldwide since MabThera/Rituxan launch in 1997".
Earlier this month, Roche and Ipsen revealed that a treatment they collaborated on - taspoglutide - yielded a positive outcome during a clinical study.
Taspoglutide went head-to-head in the trial with sitagliptin (Januvia) and a placebo therapy for the management of diabetes.Other news stories from 07/12/2009
Read more in the Zenopa News Archive
How this news is generated
|  |
|
